Continuation Study for Latozinemab

Status:
Enrolling by invitation

Trial end date:
2027-11-30

Target enrollment:

Participant gender:

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Phase 3

Alector Inc.